Survival benefit of ixazomib, lenalidomide and dexamethasone (IRD) over lenalidomide and dexamethasone (Rd) in relapsed and refractory multiple myeloma patients in routine clinical practice

BACKGROUND: We have performed a head to head comparison of all-oral triplet combination of ixazomib, lenalidomide and dexamethasone (IRD) versus lenalidomide and dexamethasone (RD) in patients with relapsed and refractory multiple myeloma (RRMM) in the routine clinical practice. METHODS: A total of...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:BMC Cancer
Asıl Yazarlar: Minarik, Jiri, Pika, Tomas, Radocha, Jakub, Jungova, Alexandra, Straub, Jan, Jelinek, Tomas, Pour, Ludek, Pavlicek, Petr, Mistrik, Martin, Brozova, Lucie, Krhovska, Petra, Machalkova, Katerina, Jindra, Pavel, Spicka, Ivan, Plonkova, Hana, Stork, Martin, Bacovsky, Jaroslav, Capkova, Lenka, Sykora, Michal, Kessler, Petr, Stejskal, Lukas, Heindorfer, Adriana, Ullrychova, Jana, Skacel, Tomas, Maisnar, Vladimir, Hajek, Roman
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: BioMed Central 2021
Konular:
Research Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7810195/
https://ncbi.nlm.nih.gov/pubmed/33451293
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-020-07732-1
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller